Department of Medical Oncology, Jefferson Medical College, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Biol Blood Marrow Transplant. 2012 Dec;18(12):1808-18. doi: 10.1016/j.bbmt.2012.09.012. Epub 2012 Oct 16.
We established double-haploidentical (DH) hematopoietic stem cell transplantation (HSCT) murine models to explore competitive engraftment, graft-versus-graft effect and graft-versus-host disease (GVHD). T cell-depleted (TCD) bone marrow (BM) cells from B6SJF1 (donor 1 [D1]) and B6D2F1 (donor 2 [D2]) mice achieved >90% donor engraftment when transplanted into B6CBAF1 mice. B6CBAF1 recipients survived without evidence of GVHD when undergoing HSCT with TCD-BM from 2 haploidentical donors, D1 and D2. DH-HSCT recipients had significantly higher leukocyte and neutrophil counts than single-haploidentical HSCT recipients from either D1 or D2. DH recipients consistently showed successful mixed chimerism in both BM and spleen. Two other DH-HSCT models, B6D2F1 + C3D2F1→B6C3F1 and B6CBAF1 + B6SJLF1→B6D2F1, showed similar engraftment patterns. Low-dose T cell infusion from both D1 and D2 increased the degree of early engraftment of the respective donors in BM and spleen; however, this early engraftment pattern did not determine long-term engraftment dominance. In the long term, minimally engrafted D1 BM recovered and comprised >50% of all donor- derived B, T, and natural killer cells. We conclude that early BM engraftment is determined by donor T cell immunodominance, but long-term engraftment is related to the engraftment potential of stem cells after DH-HSCT.
我们建立了双单倍体(DH)造血干细胞移植(HSCT)的小鼠模型,以探索竞争植入、移植物抗移植物效应和移植物抗宿主病(GVHD)。当从 B6SJF1(供体 1 [D1])和 B6D2F1(供体 2 [D2])小鼠中去除 T 细胞的骨髓(BM)细胞移植到 B6CBAF1 小鼠中时,超过 90%的供体被植入。当 B6CBAF1 受体接受来自 2 个单倍体供体 D1 和 D2 的 TCD-BM 的 HSCT 时,没有 GVHD 的证据,受体存活。DH-HSCT 受体的白细胞和中性粒细胞计数明显高于来自 D1 或 D2 的单倍体 HSCT 受体。DH 受体在 BM 和脾脏中始终表现出成功的混合嵌合体。另外两种 DH-HSCT 模型,B6D2F1 + C3D2F1→B6C3F1 和 B6CBAF1 + B6SJLF1→B6D2F1,显示出相似的植入模式。来自 D1 和 D2 的低剂量 T 细胞输注增加了各自供体在 BM 和脾脏中早期植入的程度;然而,这种早期植入模式并不能决定长期植入的优势。从长期来看,植入程度较低的 D1 BM 恢复,占所有供体衍生 B、T 和自然杀伤细胞的>50%。我们得出结论,早期 BM 植入是由供体 T 细胞免疫优势决定的,但长期植入与 DH-HSCT 后干细胞的植入潜力有关。